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6-Methylcoumarin (6MC) is a semisynthetic coumarin with important in vitro and in vivo anti-
inflammatory activity. In order to continue the pre-clinical characterization of this molecule, in vitro 
intestinal permeability, plasma profile and tissue distribution after oral administration in rats were studied. 
The permeability of 6MC was evaluated by the Caco-2 cellular model in both the apical-basal (A-B) 
and basal-apical (B-A) directions. The pharmacokinetics and biodistribution were evaluated in rats after 
oral and intraperitoneal administration at doses of 200 mg/kg. Transport experiments with Caco-2 cells 
showed that 6MC presented high permeability at all concentrations evaluated. This finding suggested 
that 6MC could be transported across the gut wall by passive diffusion. The plasma concentration-time 
curve showed that the maximum concentration (Cmax) was 17.13 ± 2.90 µg/mL at maximum time 
(Tmax) of 30 min for the oral route and Cmax 26.18 ± 2.47 µg/mL at 6.0 min for the intraperitoneal 
administration, with elimination constant of (Ke) 0.0070 min-1 and a short life half time of (T1/2) lower 
that 120 min. The distribution study showed that 6MC has high accumulation in the liver, and widespread 
distribution in all the organs evaluated. 
Uniterms: 6-Methylcoumarin/Pharmacokinetics/rats. 6-Methylcoumarin/distribution. Intestinal 
permeability/study. Intestinal permeability/study/In vitro. 
INTRODUCTION
The oral route is the most common route for 
administration of new drugs, as it is considered the safest 
and most convenient. However, it also has limitations, as 
the drug must be absorbed from the site of absorption to 
the systemic circulation, and then distributed to the target 
organs, in order to produce its pharmacological effect 
(Hedaya, 2007).
According to the Biopharmaceutics Classification 
System (BCS) of the US Food and Drug Administration, 
drugs are classified based on two intrinsic properties 
that control their oral absorption: aqueous solubility and 
intestinal permeability (Amidon et al., 1995). Knowledge 
of these drug properties not only assists in the classification 
of a drug in the BSC, but also guides the selection of 
candidate drugs during the drug development process 
(Griffin, O´Dricoll, 2008).
Solubility is one of the properties that most 
influences bioavailability due to its role in dissolution 
process according to the Noyes Whitney (Jambhekar, 
Breen, 2013). Since solubility is a thermodynamic 
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parameter that defines the amount of material that can 
dissolve in a given solvent at equilibrium, it is one of 
the most critical and widely studied physical-chemical 
attributes of candidate drugs (Wei-Qin, 2008).
Permeability, meanwhile, is the property that 
determines the speed at which a dissolved drug passes 
through the intestinal wall and reaches the systemic 
circulation. Permeability is considered one of most 
important features in the absorption of drugs. This 
is a complex kinetic process dependent on several 
physiological, physiochemical properties of the drug, and 
on the biophysiochemical properties of a gastrointestinal 
barrier membrane. Different mechanisms of permeation 
through biological barriers have been described, the most 
important ones being passive diffusion (transcellular 
and paracellular), active uptake, and efflux transport 
(Fagerholm, 2007; Matsson et al., 2005).
Likewise, knowledge of the pharmacokinetic 
profiles allows us to characterize compounds in terms of 
their bioavailability and desirable action of duration. Four 
pharmacokinetic (PK) parameters are the most useful in 
characterizing the in vivo disposition of a compound: (i) 
clearance (Cl, units of volume/time), a measure of the 
ability of the body to eliminate a compound; (ii) volume 
of distribution (Vd, units of volume), the apparent volume/
space in the body that contains the compound; (iii) half-
life (t1/2, units of time), the time taken for a compound 
to decrease to half of its initial concentration in the fluid 
or tissue in which it is measured in (e.g., plasma), and 
(iv) bioavailability (F, unitless, often expressed as %), 
the fraction of a compound that reaches the systemic 
circulation following non-intravenous administration 
(Fan, De Lannoy, 2014). Meanwhile, biodistribution 
studies describe the transit of a drug through the organism, 
the anatomic sites reached by the drug when it is in the 
systemic circulation, and the sites where it can accumulate 
(Hedaya, 2007).
On the other hand, some simple and complex 
coumarins have shown different biological activities, 
such as antibacterial, effects on the cardiovascular 
system, effects on the central nervous system, antioxidant 
activities, cytotoxicity, and anti-inflammatory properties 
(Grazul, Budzisz, 2009; Kidane et al., 2004; Beillerot et 
al., 2008; Anand, Singh, Singh, 2012; Sashidhara et al., 
2011; Kang et al., 2009; Li et al., 2011; Hoult, Paydt, 
Paya, 1996). Furthermore, 6-methylcoumarin (6MC, 
Figure 1), another simple coumarin, has shown important 
anti-inflammatory activity in in vivo and in vitro models 
(Cárdenas et al., 2014).
A l t h o u g h  6 M C  h a s  s h o w n  r e m a r k a b l e 
pharmacological effect, knowledge of its permeability, 
concentration-time and distribution is essential for 
understanding its biopharmaceutical profile. Thus, the 
aim of this work was to study the in vitro permeability 
and in vivo pharmacokinetics after oral and intraperitoneal 
administration in Wistar rats, in order to complete the 
biopharmaceutical characterization of 6MC.
MATERIAL AND METHODS
Chemical reagents 
6-Methylcoumarin (6MC, Sigma; St. Louis, MO, 
USA); trichloroacetic acid (Analytical grade, Merck, 
Darmstadt, Germany); acetic acid, methanol (HPLC grade, 
Merck, Darmstadt, Germany), and water HPLC grade 
were prepared by the MilliQ Plus system (Millipore Co., 
France). 
Animals
Twelve-week-old Male Wistar rats were obtained 
from the animal house of the Pharmacy Department 
of the Universidad Nacional de Colombia. The assays 
were carried out in accordance with the international and 
local ethical guidelines on the use and care of laboratory 
animals. The local Research Ethics Committee (Act 
03/2012 Faculty of Science) approved this study.
Drug analysis
For all the analyses, an Agilent 1100 Series HPLC 
chromatograph was used. For the permeability studies, a 
Phenomenex reversed phase column (Macclesfield, UK) 
Bondclone C-18 (150 x 3.9 mm; 10 µm) was used. The 
mobile phase was composed of A) water: methanol: acetic 
acid (95:5:1 v/v) and B): methanol: acetic acid (100:1 v/v); 
ratio 80:20 (A:B), under isocratic flow 1.0 mL/min. The 
analytical wavelength was 321 nm, and samples of 10 mL 
were injected. 
For the pharmacokinetics and tissue distribution, a 
Phenomenex reversed phase column (Macclesfield, UK) 
Bondclone C-18 (150 x 3.9 mm; 10 µm) was used. The 
mobile phase was composed of A) water: methanol: acetic 
acid (95:5:1 v/v) and B): methanol: acetic acid (100:1 
v/v) as gradient, for 32 min, at a flow rate of 1 mL/min, as 
FIGURE 1 - Chemical structure of 6-methylcoumarin.
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follows: 0 to 14 min: 0 % B to 50 % B; 14 to 23 min: 50 % 
B; 23 to 24 min: 50 % B to 0 % B; 24 to 32 min: 0 % B. UV 
detection was performed at 321 nm. The injection volume 
was 50 mL. The data were processed using the software 
program Value Solution Chemstation® (ChemStation for 




Caco-2 cells (ATCC:HTB-37) were cultured in 
high-glucose DMEM (Gibco, USA) supplemented 
with 10% fetal bovine serum and 1% non-essential 
amino acids (Gibco, USA), at 37 °C in a humidified 
5% CO2 atmosphere, until the cells reached 80-90% 
confluence. For the transport experiments, 100,000 cells 
(passages 113–115) were harvested and seeded on each 
polycarbonate insert (0.6 cm2, 0.4 μm pore size; Millipore, 
USA), and allowed to grow and differentiate for 21–28 
days prior to the experiments, as described previously by 
Kratz et al. (2012). 
Transport experiments
The determination of in vitro intestinal permeability 
of 6MC was carried out under sink conditions in a series 
of pH-gradient bidirectional transport experiments with 
Caco-2 cells. Before the experiments, cell monolayers 
were rinsed with Hank’s balanced salt solution (HBSS) 
and equilibrated for 30 min at 37 °C. The integrity 
of the monolayers was assessed before and after the 
experiments, by transepithelial electrical resistance 
(TEER) measurement. Only monolayers with TEER 
values above 200 Ωcm2 were considered.
A stock solution of 6MC (10 mM DMSO) was 
diluted to final concentration of 10, 25, 50 or 100 µM 
in HBSS pH 6.5 (apical transport buffer) or pH 7.4 
(basolateral transport buffer). Bidirectional experiments 
(apical-to-basolateral [AB] and basolateral-to-apical 
[BA]) were initiated by adding 6MC solutions to the 
donor compartment, and fresh buffer to the acceptor 
compartment. Caco-2 cell monolayers were incubated for 
1 h at 37 °C under constant stirring (150 rpm). Receiver 
compartments were sampled at 0, 15, 30, 45 and 60 min, 
refilled with an equivalent amount of transport buffer, 
and samples were submitted to analysis by HPLC/UV. 
Apparent permeability coefficients (Papp) were calculated 
from the equation
where ΔQ/Δt is the steady-state flux (mol/s), C0 is the initial 
concentration in the donor chamber at each time interval 
(mol/mL), and A is the surface area of the filter (cm2). 
Carbamazepine (CBZ) (50 µM) and hydrochlorothiazide 
(HCT) (200 µM) were used as controls. The data are 
presented as means ± SD of six independent monolayers.
Pharmacokinetic study
Male Wistar rats (12 weeks, 250 ± 10 g), with 5 
animals for each administration route, were administrated, 
by oral gavage (p.o.) or intraperitoneal (i.p.) route, with 
6MC at 200 mg/Kg, suspended in saline solution (NaCl 0.9 
%) and tween-80. 200 mg/kg was chosen as doses, since 
in previous assays (data not shown) the biopharmaceutics 
parameter, Tmax, Cmax and AUC proved be linear in a 
range of dose of 100 to 400 mg/kg.
Blood samples, 400 µl, were collected from the 
retro-orbital sinus, at 2,6,10,15,20,25,30,45,60,120, 360 
and 480 min after oral administration. After each sampling, 
the blood samples were centrifuged at 6000 rpm for 10 
min, at 4 °C to separate the plasma, and then 200 µL of 
plasma was homogenized with 200 µL of trichloroacetic 
acid (20 %), and centrifuged at 13000 rpm for 10 min. 
The supernatant was recovered for 6MC quantification 
using the HPLC-DAD method previously described. The 
maximal observed plasma concentration (Cmax) and 
corresponding sampling time (Tmax) were determined by 
visual inspection of the data.
The apparent elimination rate constant (Ke) was 
estimated by linear regression of the log-transformed 
plasma concentrations during the terminal log-linear 
decline phase. The apparent terminal elimination half-life 
time (t1/2) was calculated as ln2/Ke. The area under the 
6MC plasma concentration-time curve from time zero to 
the last quantifiable point (AUC0-t) was calculated using the 
linear trapezoidal rule. The AUC extrapolated to infinity 
(AUC0-α) was calculated as the sum of AUC0-t, and the last 
quantifiable point was divided by the elimination rate 
constant. The apparent oral clearance (Cl/f) was calculated 
as the dose divided by AUC0-α. The apparent volume of 
distribution (V/F) was calculated as the apparent oral 
clearance divided by the elimination constant.
Tissue distribution study
Male Wistar rats (12 weeks, 250 ± 10 g) were 
administered 6MC at 200 mg/kg by oral gavage (p.o.), 
suspended in saline solution (NaCl 0.9 %). At 15, 30, 60 
and 120 min after oral administration, the animals were 
sacrificed by cervical dislocation (five animals for each 
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sampling time). The organs (liver, heart, lung, kidney and 
spleen) were removed and washed with saline solution. 
The organs were then homogenized with a same volume 
of trichloroacetic acid (20 %) in a Polytron PT-10 – 35 
(Kinematica, Newark, NJ, USA), and centrifuged at 13000 
rpm for 10 min. The supernatanat was recovered for 6MC 
quantification.
Identification of the main 6-methylcoumarin 
metabolite
To determine possible metabolites of 6MC after 
oral administration, the plasma samples were analyzed 
by LC-ESI/MS. The system consisted of a Shimadzu 
HPLC equipped with two isocratic pumps, on-line 
degasser, a Rhodyne manual injector, a UV detector and 
a mass spectrometer (Shimadzu LCMS-2010EV). The 
chromatographic parameters were the same as those used 
in the HPLC-DAD analysis. LabSolution® V.3.0 software 
was used for the data acquisition and processing. Full scan 
mass spectra were recorded at between m/z 50 and 500 in 
positive mode. Nitrogen was used as nebulizer gas at 1 L/
min, capillary voltage was 4.500 V and detector voltage 
was 1.500 V. The collision dissolution line (CDL) and 
QarrayRF voltage were both 150 V. CDL and the Heat 
Block temperature as set at 250°C. Standard samples of 
coumarin and 6MC were analyzed following the same 
methodology.
Statistical analysis
All results were expressed as the arithmetic mean of 
the values  obtained, ± the respective standard deviation. 
Simple comparisons between groups were performed 
using the Student’s t-test, with a confidence level of 95%.
RESULTS
Permeability 
Table I shows that 6MC presented a high Papp in the 
absorptive and secretory directions in Caco -2 cells. Given 
the finding of Papp values over 10-5, it is suggested that 
6MC is highly permeable in both directions. The efflux 
ratio (Papp BA/ Papp AB) of less than 2 in all cases indicates 
a passive diffusion mechanism and the absence of efflux. 
For all the concentrations evaluated, 6MC had high mass 
balance values, with average recovery of more than 70% 
in both the AB and BA directions.
The permeation of 6MC was performed in both A- B 
and B-A in the Caco-2 cellular model. Figure 2 shows the 
cumulative amount permeated (µM/cm2) in the AB and 
BA directions. The relation of the concentration versus the 
cumulative amount permeated showed a linear relationship 
proportional to concentration (in both directions), with 
determinant coefficients of 0.9903 and 0.9853 for AB and 
BA direction, respectively. This means that there is no 
saturation of the acceptor medium in any concentration 
and time during the test time.
Pharmacokinetic
The plasma samples were analyzed using an HPLC-
DAD validated method (Hernández, Ospina, Aragón, 
2014). The mean plasma concentration versus time profiles 
of 6MC are shown in Figure 3. The pharmacokinetic 
parameters calculated for 6MC in plasma are summarized 
in Table II. 
Plasma pharmacokinetics of 6-methylcoumarin in 
rats following oral administration. Data are expressed as 
mean ± SD of five animals. Dose administered 200 mg/kg.
TABLE I - Comparable Papp (cm/s) values for 6MC obtained in the absorptive (A-B), secretory (B-A) directions, and efflux ratio 
(Papp B-A/ Papp A-B)
A-B B-A
Efflux ratio
Mean SD Mean SD
10 µM 9.1E-05 2.9E-06 1.3E-04 6.1E-05 1.48
25 µM 6.8E-05 2.4E-06 6.7E-05 1.4E-06 1.06
50 µM 6.4E-05 8.3E-06 6.0E-05 5.6E-07 0.94
100 µM 9.0E-05 4.4E-06 7.3E-05 1.5E-05 0.82
CBZ 50 µM 11.4E-05 2.4E-06
HCT 200 µM 0.06E-05 0.3E-07
The data are expressed as means ± SD of six independent monolayers. Carbamazepine (CBZ) (50 µM) and hydrochlorothiazide 
(HCT) (200 µM) were used as controls.
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Maximum concentration (Cmax), Maximun 
time (Tmax), Area Under Curve from time zero to the 
last quantifiable point (AUC0-480), Area Under Curve 
extrapolated to infinite (AUC0-α), Elimination constant 
(Ke), Absortion constant (Ka), elimination half –time 
(t1/2), Apparent oral clearance (Cl/F), Apparent volume of 
distribution (V/F). Cl/f and Vd were calculated taking into 
account the soluble 6MC in the volume administered. The 
data are generated using the mean values from individual 
rats ± SD (n=5).
As shown in Table II, the Cmax, Tmax, and ABC0-
480 and ABC0- α values for intraperitoneal administration 
are higher than those obtained after oral administration. 
This fact could be explained by that fact that in the 
intraperitoneal route, absorption occurs through the 
mesenteric vessels, draining to the portal vein, and thereby 
accessing the bloodstream in less time than by the oral 
route (Turner et al., 2011), making this a more rapid 
absorption route (Morton et al., 2001).
FIGURE 2 - Transport of 6-methylcoumarin across Caco-2 cells. 
Cumulative amount of 6-methylcoumarin transported across 
Caco-2 cells in the Apical to Basolateral (A) or Basolateral to 
Apical direction (B). Data are expressed as means ± SD of six 
independent monolayers.
TABLE II - Plasma pharmacokinetics parameters of 6-methylcoumarin after oral and intraperitoneal administration in Wistar rats, 
dose 200 mg/kg
Oral Intraperitoneal
AUC0-480 (µg/mL*min) 977.2 ± 276.5 2177.0 ± 331.6
AUC0- α (µg/mL*min) 1015.4 ± 296.1 2234.9 ± 354.1
C max (µg/mL) 17.13 ± 2.90 26.18 ± 2.47
Tmax (min) 30 6.0
ke (min-1) 0.0064 ± 0.0009 0.0076 ± 0.0007
Ka (min-1) 0.3311 ± 0.0489
t ½ (min) 109.8 ± 15.0 92.3 ± 8.7
Cl/f (mL/min) 0.8 ± 0.3 0.4 ± 0.07
Vd (mL) 134.9 ± 30.4 48.8 ± 3.9
F 0.45
FIGURE 3 -  Plasma concentrat ion -  t ime profi le  of 
6-methylcoumarin after oral and intraperitoneal administration 
in Wistar rats. 
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Regarding the values obtained of ke, t1/2 and the Cl/f, 
no significant difference was found that could be attributed 
to the administration route. This fact is expected, since 
these are intrinsic parameters of the drug. 
Besides 6MC, another majority compound was 
detected in the plasma after oral administration of 6MC. 
This compound could be related to gastrointestinal 
metabolism of 6MC, since it was not found in the blood 
samples analyzed after i.p. administration. Data from the 
LC-ESI/MS were used for preliminary identification of 
the main metabolite of 6-MC. The retention times (Rt), 
UV λmax values and the molecular ions in positive mode 
are shown in Table III. 
Distribution Tissue
Using a validated HPLC-DAD method, the 
concentration of 6MC after oral administration was 
determined in liver, heart, lung, kidney and spleen 
(Figure 4).
In all the organs, 6MC concentrations were found 
to be in the range of between 0.35 ± 0.14 and 4.18 ± 0.03 
µg per g of tissue. At 15 min, the highest concentrations 
were found in plasma and liver, and the lowest in kidneys, 
heart and lungs. At 30 min, the concentration increased 
proportionally in all the organs sampled. At 60 min, the 
distribution changed; in the kidney, the concentration of 
6MC increased significantly, while the concentrations 
in the other organs decreased. At this same time point, 
the concentrations (µg/mL) were as follows; heart: 2.54 
± 0.10; plasma: 2.48 ± 0.62; spleen: 1.89 ± 0.15, lung: 
0.59 ± 0.10 lung, kidney 3.40 ± 0.31, liver 1.45 ± 0.10. In 
addition, the 6MC fraction present in the evaluated organs 
was very low, since the total 6MC found in all the organs 
tested at 30 and 60 minutes was 0.104% and the 0.046% 
of the 6MC administered, respectively.
DISCUSSION
Ideal drug candidates should have adequate 
aqueous solubility and permeability in order to achieve 
effective concentration in the target tissue (Kratz et 
al., 2012). In order to evaluate the in vitro intestinal 
permeability, transport experiments were performed on 
Caco-2 cells. These cells are able to fully polarize into 
differentiated monolayers, with well-established tight 
junctions and brush border membrane. They can also 
express several membrane transporters and metabolizing 
enzymes, allowing the measurement of functional 
permeability, both through passive diffusion and active 
transport (Kratz et al., 2012). The apparent permeability 
of 6MC was high, with values of magnitude of 10-5. 
This value is comparable with the Papp of other similar 
compounds such as umbelliferone, scopoletine, and 
coumarin, in which high permeability and no efflux were 
reported (Galkin, Fallarero, Vuorela, 2009).
The high intestinal permeability of a drug indicates 
that its transport across the gut wall does not represent 
a relevant restriction for its oral absorption. The linear 
increase in the amount of 6MC permeated, indicating that 
its transport across the gut wall, is probably mediated by 
passive diffusion, and the low efflux values in the different 
concentrations evaluated, indicating that efflux does not 
represent an interference for absorption (Galkin, Fallarero, 
Vuorela, 2009).
The BCS considers that a drug has high aqueous 
solubility if its maximum dose is completed dissolved 
in 250 ml of pH 1-7.5 buffered aqueous solution (Wei-
Qin, 2008). According to this definition, it is suggested 
that 6MC has low solubility, since the dose of 6MC that 
TABLE III - The main coumarinic compounds identified by LC-ESI/MS analysis in plasma after oral administration of 
6-methylcoumarin in Wistar rats
Peak Rt (min) λmáx (nm) [M+H]+ (m/z) Compound
1 12.5 278 and 321 147 Coumarin
2 14.6 278 and 321 161 6-methylcoumarin
FIGURE 4 - Biodistribution profile of 6-methylcoumarin after 
oral administration in Wistar rats. Data expressed mean ± D.S 
of five animals. Dose administered 200 mg/kg.
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showed anti-inflammatory activity in rats is 200 mg/
kg,(Cárdenas et al., 2014) and its solubility is 0.57 ± 0.03 
µg/mL in water and buffered solutions of pH 1.2, 6.8 and 
7.4 (Cárdenas et al., 2013). As consequence, 6MC can be 
classified as a class II compound (Low solubility/High 
permeability) accord to the BCS, when the absorption 
across the gut wall is limited mainly by solubility.
The concentration-time profiles (Fig 3) showed fast 
absorption, but low plasma concentration in relation to the 
dose administered (10.25 ± 0.72 y 26.18 ± 2.47 µg/mL 
oral and intraperitoneal via respectively). This fact may 
be related to the high clearance rate (CL/F) and possibly, 
a high rate of metabolism after administration of 6MC.
Regarding other coumarins orally administered 
in rats, 6MC have a similar t1/2 to that reported for 
daphnoterine and daphnetin (t1/2 of 93 ± 26 and ± 262.23 
96.31 min respectively) (Wei et al., 2015; Lin et al., 2005; 
Zhang et al., 2014). For coumarin, half-lives (t1/2) of 
between 60-240 h were found in humans and other species, 
such as rats (Lake, 1999).
The absolute bioavailability is defined as the 
fraction of administered dose that reaches the systemic 
circulation, compared to the fraction of intravenously 
administered dose, while the relative bioavailability is the 
fraction of administered dose that reaches the systemic 
circulation compared to an administration route other 
than the intravenous one (Haidar, Kwon, Lionberger, 
2008). Due to the low solubility of 6MC, its intravenous 
administration was not possible; therefore, the value 
reported for bioavailability in this study corresponds 
to the intraperitoneal route, a parenteral route with 
rapid absorption (Turner et al., 2011). The relative 
bioavailability found for 6MC was 0.45 (45%) which 
is higher than that reported for coumarin administered 
orally in humans, which showed rapid absorption from 
the gastrointestinal tract and was rapidly metabolized 
by the first-pass effect, resulting in only 2-6 % found 
intact in the systemic circulation (Felter et al., 2006). 
Similarly, other authors have described the behavior of 
high metabolization and low plasma concentrations of 
coumarin, indicating an absolute bioavailability of only 
1.5 % (Hoult, Paydt, Paya, 1996).
As shown in Figure 4, in all the organs tested at 
60 min, the 6MC concentration decreased to half the 
initial concentration after 30 min. This fact suggests 
that 6MC is rapidly eliminated from the systemic 
circulation (t1/2 less than 2 hour and high apparent 
clearance) or extensively metabolized. Previous studies 
on the in vivo metabolism of coumarins reported that 
coumarins are metabolized mainly into two kinds of 
compounds: its hydroxyl derivatives, and its smaller 
acid derivatives, such as ortho-hydroxyphenyllactic 
acid, ortho-hydroxyphenylacetic acid and ortho-
hydroxyphenylpropionic acid (Lake, 1999).
In this study, some peaks presented pseudo-
molecular ions related to known coumarin metabolites. 
Although the highest peak observed (Rt 14.6 min) 
was the non-metabolized 6MC, metabolites could be 
observed and tentatively identified, such as coumarin 
(Rt = 12.5). These results suggest that demethylation 
is probably the primary biotransformation for 6MC 
in order to increase the polarity of the molecule. This 
demethylation reaction is reported for other compounds 
such as lobeglitazone (Song et al., 2014), and for the 
Ostol, a coumarinic compound where the demethylation 
has been described as a phase I metabolic reaction of 
(Yuan et al., 2009). Another peak (Rt = 11.8, [M+H]+ 
(m/z) 657.3) was observed, but was not possible to 
propose a structure, because the molecular weight is not 
comparable with the common metabolites of coumarin 
structure. The conjugation with glutathione (GSH) is 
common for coumarin (Lake, 1999).
The biodistribution after oral administration in 
the studied organs evidenced a high accumulation of 
6MC in the plasma and in the most irrigated organs; 
similar behavior was found for 6MC biodistribution 
after intraperitoneal administration (Hernández, Ospina, 
Aragón, 2014). High levels of accumulation were found 
in the liver and kidney, which suggests that these organs 
are involved in the processes of metabolism, elimination 
and excretion of 6MC. The high accumulation in all organs 
evaluated is in concordance with the high Vd found both 
administration routes (p.o and i.p), indicating that 6MC is 
widely distributed throughout the body.
CONCLUSION
Some biopharmaceutical properties of 6MC 
were determined in order to increase the preclinical 
characterization of this promising drug. It was found that 
6MC is highly permeable and according to the BCS, may 
be considered a compound class II. The biopharmaceutical 
and pharmacokinetic parameters were determined 6MC 
after oral and intraperitoneal administration in Wistar 
rats. It was found that the compound has a rapid removal 
times, as reflected in its short half-life of 110 min under 
constant removal of 0.0070 min -1. A large volume of 
distribution was also observed in the biodistribution 
study, indicating extensive distribution. Coumarin was 
identified as the major metabolite 6-methylcoumarin, 
suggesting desmetililation as the first reaction 6MC 
biotransformation.
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